Evaluation of two rapid tests for detection of maternal endocervical group B streptococcus: Enzyme-linked immunosorbent assay and gram stain

1994 ◽  
Vol 45 (1) ◽  
pp. 77-77
Author(s):  
Z.J. Hagay ◽  
A. Miskin ◽  
R. Goldchmit ◽  
A. Federman ◽  
A. Matzkel ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Group B Streptococcus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Gram Stain ◽  
Rapid Tests ◽  
Group B

scholarly journals Inhibition Enzyme-Linked Immunosorbent Assay for Serotyping of Group B Streptococcal Isolates

1999 ◽  
Vol 37 (8) ◽  
pp. 2564-2567 ◽  
Author(s):  
Gayathri Arakere ◽  
Aurea E. Flores ◽  
Patricia Ferrieri ◽  
Carl E. Frasch
Keyword(s):  
Immunosorbent Assay ◽  
Group B Streptococcus ◽  
Epidemiological Studies ◽  
Enzyme Linked Immunosorbent Assay ◽  
Vaccine Production ◽  
Elisa Method ◽  
Serious Infections ◽  
Specific Antisera ◽  
Selection For ◽  
Group B

Group B Streptococcus (GBS) is one of the most common organisms causing neonatal sepsis as well as serious infections in adults. Serotyping the organism is important in studying the epidemiology of the disease as well as deciding a course of treatment. There are several methods available for serotyping. Most of them need high-titered sera and are not quantitative. We are reporting a new inhibition enzyme-linked immunosorbent assay (ELISA) for serotyping which is sensitive and specific compared to the conventional methods but does not need high-titered serotype-specific antisera, as the specificity is controlled by the polysaccharide coating on the ELISA plates. The method can also be quantitative, and we have measured polysaccharide elaborated by different serotype V strains. Thus, the inhibition ELISA method will be useful in serotyping for epidemiological studies, assessing virulence, and performing strain selection for vaccine production.

scholarly journals Development and Validation of Enzyme-Linked Immunosorbent Assay for Group B Streptococcal Polysaccharide Vaccine

Vaccines ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 545
Author(s):  
A-Yeung Jang ◽  
Min-Joo Choi ◽  
Yong Zhi ◽  
Hyun-Jung Ji ◽  
Ji-Yun Noh ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Large Scale ◽  
Capsular Polysaccharide ◽  
Vaccine Development ◽  
Group B Streptococcus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Samples ◽  
Igg Antibody ◽  
Logistic Method ◽  
Group B

Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of neonatal sepsis and meningitis in infants. Limitations of prenatal GBS screening and intrapartum antibiotic prophylaxis render developing GBS vaccines a high priority. In this study, we developed an enzyme-linked immunosorbent assay (ELISA) for the practical and large-scale evaluation of GBS capsular polysaccharide (PS) vaccine immunogenicity against three main serotypes, Ia, III, and V. GBS-ELISA was developed and subsequently validated using a standardized curve-fitting four-parameter logistic method. Specificity was measured using adsorption of serum with homologous and heterologous PS. Homologous adsorption showed a ≥75% inhibition of all three serotypes, whereas with heterologous PS, IgG GBS-ELISA inhibited only ≤25% of serotypes III and V. However, with serotype Ia, IgG antibody levels decreased by >50%, even after adsorption with heterologous PS (III or V). In comparison, the inhibition opsonophagocytic killing assay (OPA) of serotypes Ia GBS exhibited a reduction in opsonophagocytic activity of only 20% and 1.1% for serotypes III and V GBS, respectively. The precision of the GBS-ELISA was assessed in five independent experiments using four serum samples. The coefficient of variation was <5% for all three serotypes. This standardized GBS-ELISA would be useful for GBS vaccine development and its evaluation.

scholarly journals Quantitation of IgG Antibodies to Type Ia Group B Streptococcal Type-Specific Polysaccharides Measured by Enzyme-Linked Immunosorbent Assay

1990 ◽  
Vol 64 (7) ◽  
pp. 840-846 ◽  
Author(s):  
Masako SUGIYAMA ◽  
Masayoshi KOJIMA ◽  
Yukiko YASUDA ◽  
Yoshihiro HORI ◽  
Yasunobu NISHIYAMA ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Type Ia ◽  
Group B

scholarly journals Field Evaluation of Four Rapid Tests for Diagnosis of HIV Infection in Panama

2016 ◽  
Vol 54 (4) ◽  
pp. 1127-1129 ◽  
Author(s):  
Sandra I. Juarez ◽  
Aurelio E. Nuñez ◽  
Margginna M. Aranda ◽  
Dalis Mojica ◽  
Andrea A. Kim ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Immunosorbent Assay ◽  
Field Evaluation ◽  
Enzyme Linked Immunosorbent Assay ◽  
Field Validation ◽  
Rapid Tests ◽  
Testing Algorithm ◽  
Testing And Counseling

Four HIV rapid tests were subjected to field validation in Panama and compared to an enzyme-linked immunosorbent assay/Multispot-based testing algorithm. The sensitivities of Determine, Uni-Gold, SD Bioline, and INSTI were 99.8%. The specificities of Determine, SD-Bioline, and Uni-Gold were 100%, and the specificity of INSTI was 99.8%. On the basis of these data, we determined that these rapid tests can be used in an appropriate algorithm to diagnose HIV infection and are suitable for use in testing and counseling settings in Panama.

scholarly journals Strategy for Cross-Protection among Shigella flexneri Serotypes

1999 ◽  
Vol 67 (2) ◽  
pp. 782-788 ◽  
Author(s):  
Fernando R. Noriega ◽  
Fang Ming Liao ◽  
David R. Maneval ◽  
Shuxun Ren ◽  
Samuel B. Formal ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Guinea Pigs ◽  
Shigella Flexneri ◽  
Cross Protection ◽  
Enzyme Linked Immunosorbent Assay ◽  
The Novel ◽  
Significant Protection ◽  
Wild Type ◽  
Slide Agglutination ◽  
Group B

ABSTRACT Based upon the lipopolysaccharide (LPS) structure and antigenicity of Shigella group B, a strategy for broad cross-protection against 14 Shigella flexneri serotypes was designed. This strategy involves the use of two S. flexneri serotypes (2a and 3a), which together bear the all of the major antigenic group factors of this group. The novel attenuated strains used in these studies were S. flexneri 2a strain CVD 1207 (ΔguaB-A ΔvirG Δset1 Δsen) and S. flexneri 3a strain CVD 1211 (ΔguaB-A ΔvirG Δsen). Guinea pigs were immunized with an equal mixture of these strains and later challenged (Sereny test) with a wild-typeS. flexneri serotype 1a, 1b, 2b, 4b, 5b, Y, or 6 strain of demonstrated virulence in the same model. Guinea pigs that were immunized with these two vaccine strains produced serum and mucosal antibodies that cross-reacted with all the S. flexneri serotypes tested (except of S. flexneriserotype 6) as assessed by enzyme-linked immunosorbent assay, immunoblotting, and slide agglutination. Furthermore, the combination vaccine conferred significant protection against challenge withS. flexneri serotypes 1b, 2b, 5b, and Y but not with serotypes 1a, 4b, or (as predicted) 6.

scholarly journals Estimation of Group B Streptococcus Type III Polysaccharide-Specific Antibody Concentrations in Human Sera Is Antigen Dependent

1998 ◽  
Vol 66 (12) ◽  
pp. 5848-5853 ◽  
Author(s):  
Reva Bhushan ◽  
Bascom F. Anthony ◽  
Carl E. Frasch
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Conjugate Vaccine ◽  
Group B Streptococcus ◽  
Antigenic Specificity ◽  
Enzyme Linked Immunosorbent Assay ◽  
Type Iii ◽  
Human Sera ◽  
Group B

ABSTRACT The presence of immunoglobulin G (IgG) antibodies against group B streptococcus (GBS) type III polysaccharide (PS) has been correlated with protection against GBS disease. The GBS type III PS is structurally similar to the pneumococcal type 14 PS, differing only in the presence of sialic acid residues. Four different preparations of GBS type III PS were evaluated for their specificity in enzyme-linked immunosorbent assay (ELISA): free PS, free PS mixed with methylated human serum albumin (mHSA), PS conjugated to biotin and PS conjugated to human serum albumin. Three groups of human sera were used to evaluate these PS preparations: sera from recipients of a GBS PS vaccine, sera from women receiving a GBS type III PS-tetanus toxoid conjugate vaccine, and sera from nonimmunized healthy women of childbearing age. Estimated antibody concentrations were different depending on the PS preparation used. Using any of the four preparations, we were able to measure ≤0.05 μg of IgG antibody to the GBS type III PS per ml. The specificity of the assay was determined by competitive inhibition with homologous and heterologous PS. The pneumococcal type 14 PS did not inhibit binding of antibody to the native GBS type III PS in sera from adults receiving the GBS PS vaccine or in sera from nonimmunized adults (except serum G9). The pneumococcal type 14 PS inhibited 50% in sera from recipients of GBS type III conjugate vaccine and in serum G9 when GBS type III PS conjugated to biotin or to HSA was used as antigen in ELISA. These data show that free GBS type III PS or PS mixed with mHSA is a sensitive and specific antigen for ELISA and that conjugation can alter the antigenic specificity of a PS.

Sign in / Sign up

Export Citation Format

Share Document